pharmaphorum Podcast

At ASCO 2025, Eisai presented data from its oncology portfolio, including in hepatocellular carcinoma and endometrial cancer.

In a post-Congress conversation, web editor Nicole Raleigh spoke with Dr Corina Dutcus, senior vice president and oncology global clinical development lead at Eisai, who discussed the data and the company’s continued commitment to innovation in the oncological field.

Tune in to this and other ASCO 2025 conve...

Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a highly aggressive, lethal form of pancreatic cancer that accounts for more than 90% of pancreatic cancer cases.

At ASCO 2025, Actuate gave an oral presentation on positive Phase 2 combination data for elraglusib, highlighting its potential to enhance anti-tumour activity by targeting key resistance pathways and immune mechanisms in previously untreated patients with mPDAC.

In...

Melanoma is the fifth most common cancer in the UK, accounting for around 4% of all new cancer cases. While immunotherapy is a standard treatment for advanced melanoma patients, only about half of patients respond well, leaving the rest at risk of disease progression and metastases.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Phillip L’Huillier, CEO of Scancell, about how the company develops novel immunoth...

Back in May, health data company Datavant announced its plans to acquire Aetion, creating a formidable player in the real-world data space. Now that the acquisition has closed, the pharmaphorum podcast welcomes Arnaub Chatterjee, president and general manager of life sciences at Datavant, to discuss what that integration will look like -- and what the implications are for the pharma industry.

Chatterjee discusses how the acquisitio...

When it comes to CGTs, long-term follow-up care is an issue that makes patient access to these novel investigative treatments extremely limited, given the 15 years that patients must still engage with the trial after receiving the medication.

In a post-ASCO 2025 conversation, pharmaphorum web editor Nicole Raleigh spoke with Dr Pamela Tenaerts, chief medical officer at Medable, about the company’s new digital-first model to handle ...

In a new pharmaphorum podcast, Aoife Brennan, CEO of Climb Bio, discusses the treatment of immune-mediated diseases.

Climb Bio is a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, and Brennan talks about the potential of B-cell depletion therapies, as well as the challenges and opportunities in developing novel biotechnology.

Brennan also speaks to being a female leader in this field.

You ...

For AI to truly revolutionise drug discovery, it must move beyond pattern recognition and predictive analytics to include causality, which is essential for technical and regulatory success in drug discovery.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Ben Sidders, chief scientific officer at Biorelate, a company leveraging advanced data science methods to transform the focus and impact of drug discovery and...

Radiopharmaceutical therapy has attracted increasing attention in the treatment of refractory diseases that are not sensitive to current therapies, such as in oncology.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Greg Piefer, founder and CEO of SHINE Technologies, a nuclear fusion company mastering more immediate applications of fusion – such as in producing cancer-fighting medicine.

Piefer provides an over...

The second annual HLTH Europe conference brought together health leaders, start-ups, investors, and developers from across the globe for a mid-year pulse check on where healthcare innovation stands today – and where it’s headed next.

Amid economic uncertainty and shifting regulatory priorities, pharma, health tech, and care delivery are all racing to prove value and scale innovation. In this special extended episode of the pharmaph...

In today's healthcare landscape, there is a pressing need for quantitative methodologies that include the patients' perspective in any treatment decision.

In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Marc Buyse, founder of IDDI and One2Treat, and also co-founder of CluePoints, about his recent work as one of the editors of – and a chapter contributor to – the first edition of "𝘏𝘢𝘯𝘥𝘣𝘰𝘰𝘬 𝘰𝘧 𝘎𝘦𝘯𝘦𝘳...

At this year’s Veeva R&D and Quality Summit, it was revealed that Novo Nordisk and Veeva have entered into a new partnership for clinical development.

In this episode of the pharmaphorum podcast, web editor Nicole Raleigh spoke with Stephanie Bova, chief digital officer at Novo Nordisk, and Rik van Mol, SVP R&D and Quality at Veeva, about the partnership, Novo aiming to accelerate clinical trials and launches by uniting bus...

The JCA process was passed into law by the European Union in 2022. The Joint Clinical Assessment is a process that will systematically assess all available clinical evidence for new drugs. Rolled out in stages, starting with oncology drugs and advanced therapy medicinal products this year, it will be fully implemented by 2030.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Tommy Bramley, SVP of market access a...

Originally employed in atomic physics, mass spectrometry is now an indispensable tool in modern science, and importantly medical science.

In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Melissa Sherman, CEO of MOBILion Systems, a company pioneering next-generation separation science, by innovating best-in-class instruments that deeply, accurately, and efficiently characterise complex molecules.

Sherman discusses...

Onsite at ASCO 2025 in Chicago, web editor Nicole Raleigh sat down with Dr Stacy Lindborg, CEO of IMUNON, to discuss the company’s oral presentation at the Congress from the Phase 2 OVATION 2 study of IMNN-001, an IL-12 immunotherapy, in women with newly diagnosed advanced ovarian cancer – since published in the peer-reviewed journal Gynecologic Oncology today.

Dr Lindborg shares her journey to her present role, the true potential ...

Osteosarcoma is an extremely challenging and often aggressive cancer that has particular treatment challenges due to location, changing genotypes, and high recurrence rates. It mostly affects children and young adults under 20 years of age.

In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Paul Romness, president and CEO of OS Therapies, a company focused on the identification, development, and commercialisation o...

In healthcare, some of the most meaningful innovations happen when the right people are brought together in the right place. True progress depends on systems and infrastructure designed to connect ideas, people, and expertise across sectors.

Citylabs 4.0, now open in the heart of Manchester’s Knowledge Quarter on the Oxford Road Corridor, was built with exactly that goal in mind. Bringing the NHS, academia, and life sciences organi...

Boehringer Ingelheim’s data presented at ASCO 2025 reflected the company’s broad pipeline and growing body of evidence supporting innovative therapies for various cancers.

In a pharmaphorum podcast recorded onsite at the Congress, web editor Nicole Raleigh spoke with Itziar Canamasas, global head of oncology at Boehringer Ingelheim, for a discussion of the unmet needs in oncology and some of the specifics of the company’s data pres...

Trends can be predicted, and trends can unfold. Here, Liz Beatty – co-founder and chief strategy of Inato – speaks to the beginnings of a new era in drug development brought on by key technological advances in AI.

Historically, large urban academic centres have conducted the majority of clinical trials, leading to such issues as inaccessibility, lack of representation, and intense competition for participants. With growing industry...